Clinical trials: Dementia Moderate
Alzheimer Disease
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
- Trial name
- NCT02248116
- Testing
- Talsaclidine
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102.
- Trial name
- NCT00606476
- Testing
- Bapineuzumab (AAB-001)
- Where
- 29 sites in United States
- Volunteers
- 194 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Dementia, Dementia, Mild
Cognitive Stimulation in Daily Activities for People Living With Early to Middle Stage Dementia
The goal of this study is to test the effect of CS-ADL is on people living with early to middle stage dementia. The study also aims to evaluate the feasibility of conducting larger-scale research of CS-ADL.
- Conditions
- Dementia, Dementia, Mild, Dementia Moderate
- Trial name
- CS-ADL (NCT06147479)
- Testing
- CS-ADL (Cognitive stimulation in Activities of Daily Living)
- Where
- Ireland
- Volunteers
- 16 people
- Sponsor
- National University of Ireland, Galway, Ireland
Alzheimer's Disease
Double Blind Study of Trp01 in Patients With Alzheimer's Disease
The purpose of this study is to determine whether tryptophan is effective in the treatment of mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT00202124
- Testing
- Tryptophan
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Queen's University
Alzheimer Disease
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to…
- Trial name
- NCT00297362
- Testing
- Galantamine hydrobromide
- Volunteers
- 344 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Late Onset Alzheimer Disease
Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms
Pharmacological treatment of AD is currently based on cholinesterase inhibitors (ChEI) and memantine, which have been shown to lead to modest, although effective, clinical benefits.
- Trial name
- NCT03349320
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Alzheimer's Disease
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01689246
- Testing
- TRx0237 150 mg/day, TRx0237 250 mg/day
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 891 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer Disease
TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease
This is an expanded access program (EAP) for eligible participants. This program is designed to provide continued access to TRx0237 to individual patients with early and mild-moderate Alzheimer's disease who do not qualify for…
- Trial name
- NCT03539380
- Testing
- TRx0237
- Sponsor
- TauRx Therapeutics Ltd
Moderate to Severe Dementia
Dementia Moves: Protocol for a Feasibility Study
Most long-term care (LTC) residents live with frailty and dementia and the proportion with more advanced cognitive impairment is increasing.
- Trial name
- NCT06400108
- Testing
- Dementia Moves
- Volunteers
- 16 people
- Sponsor
- Dalhousie University
Dementia, Alzheimer Disease
Digital Interventions in Neuro-Rehabilitation: Gotcha!
Aims and background Everyone forgets the names of people they should know at times. Having dementia makes this problem worse. People with dementia have told expressed they forget the names of people they care about and this can…
- Conditions
- Dementia, Alzheimer Disease, Anomia
- Trial name
- NCT04570215
- Testing
- Gotcha! Therapy application, Gotcha Therapy application: Maintenance
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
Neurodegenerative Diseases, Behavioral Symptoms
Impact of Harp Therapy on Behavioral Disorders in Nursing Home Residents With Neurodegenerative Disease (ARPE)
The ARPE study looked at whether weekly harp therapy sessions could reduce behavioral problems in older adults living in memory care units of a nursing home (EHPAD).
- Conditions
- Neurodegenerative Diseases, Behavioral Symptoms, Dementia, Agitation
- Trial name
- ARPE (NCT07748013)
- Testing
- Harp therapy (receptive music therapy)
- Where
- France
- Volunteers
- 25 people
- Sponsor
- LNA SANTE
Older Adults With Mild to Moderate Level of Dementia
Activity Scheduling for Older Adults With Dementia
This study is to evaluate the results from an intervention designed to encourage older adults with dementia for their engagement in activities through their active participation of activity scheduling (AS).
- Trial name
- AS (NCT03890796)
- Testing
- Activity Scheduling, Educational
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The Hong Kong Polytechnic University
Alzheimer's Disease
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
The primary purpose of this study is to assess the safety and tolerability of TRx0237 when taken at the same time as acetylcholinesterase inhibitors (i.e., donepezil, galantamine, or rivastigmine) and / or memantine to treat…
- Trial name
- NCT01626391
- Testing
- TRx0237
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer's Disease
OmegAD (Omega-3 and Alzheimer's Disease)
Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA.
- Trial name
- NCT00211159
- Testing
- EPAX 1050TG
- Where
- Sweden
- Volunteers
- 204 people
- Sponsor
- Karolinska University Hospital
Dementia
Multisensory Physical Exercises in People With Cognitive Impairment
The main objective of the study is to evaluate the efficacy of a combined training program of physical exercise and multisensory stimulation (Physiocognitive Integration) in people with mild/moderate cognitive impairment.
- Trial name
- NCT05295966
- Testing
- Cognitive therapy, Physiocognitive Integration
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Universidad Rey Juan Carlos
Alzheimer Disease, Alzheimer Dementia
Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients
This placebo-controlled, double blind study evaluates the treatment effects of adding a multi-pathway botanical dietary supplement (ReBuilder) to the standard treatment regimens of subjects diagnosed with mild or moderate stage…
- Trial name
- NCT03611439
- Testing
- ReBuilder
- Volunteers
- 50 people
- Sponsor
- Genescient Corporation
Breast Cancer, Chronic Myeloproliferative Disorders
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
RATIONALE: Alemtuzumab and glucocorticoids, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00410657
- Testing
- alemtuzumab, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Huntington Disease
Symptomatic Therapy for Patients With Huntington's Disease
Based on the previous symptomatic treatment of Chinese HD patients, this study intends to further optimize the treatment regimen of Chinese HD patients so as to further improve the prognosis of patients.
- Trial name
- NCT04071639
- Testing
- Haloperidol 2Mg Tab, Risperidone 1Mg Tab, Zoloft 50Mg Tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Dementia, Alzheimer Type
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors.
- Trial name
- NCT00505167
- Testing
- Memantine, Donepezil
- Where
- 3 sites in Spain
- Volunteers
- 64 people
- Sponsor
- Hospital Miguel Servet
Dementia
Doll Therapy on Patients With Moderate and Severe Dementia
Doll therapy is one of the non-pharmacological methods that can be practiced in managing the symptoms of dementia patients. Nurses can practice doll therapy independently, and literature reports that it has positive effects on…
- Trial name
- NCT04120103
- Testing
- Doll therapy, Routine nursing care
- Where
- Turkey (Türkiye)
- Volunteers
- 29 people
- Sponsor
- Aksaray University Training and Research Hospital